Introduction
============

Cognitive decline associated with advancing age is one of the most important challenges currently facing health care providers, both in the spheres of diagnosis and management and in the delivery of supportive services to the patient and caregivers.[@b1-cia-10-1881]--[@b3-cia-10-1881] The spectrum of neurocognitive decline from subjective cognitive complaints to mild cognitive impairment (MCI) and ultimately to a progressive dementia syndrome places the primary care physician at the forefront in providing care for a growing number of cognitively impaired older patients, the majority of whom reside in the community. While systematic population screening for cognitive impairment has not been shown to be effective,[@b4-cia-10-1881],[@b5-cia-10-1881] the assessment of patients who are referred to the clinic for cognitive symptoms and decreased cognitive function is recommended.[@b6-cia-10-1881]--[@b8-cia-10-1881]

MCI is a clinical syndrome that has been clearly defined, both in the clinical situation and in research settings.[@b7-cia-10-1881],[@b9-cia-10-1881],[@b10-cia-10-1881] MCI is prevalent in the older population, with some 15% of those older than 65 years having this condition, with a range of 3%--42% reported in community-based studies.[@b11-cia-10-1881]--[@b13-cia-10-1881] The presence of predominant memory complaints and impairment alongside the preservation of function in instrumental daily activities suggests amnestic MCI, and this is generally considered to represent an early stage of Alzheimer's disease.[@b9-cia-10-1881],[@b10-cia-10-1881],[@b14-cia-10-1881] Approximately 10% of patients with MCI will progress to dementia annually.[@b15-cia-10-1881],[@b16-cia-10-1881]

In a longitudinal archival study,[@b17-cia-10-1881] it was shown that changes in visual-spatial perception sometimes appear in the preclinical phase of dementia as early as 3 years before the diagnosis of dementia, while memory decline occurs some 2 years before diagnosis.

The purpose of this study was to examine whether the use of visual-spatial perception testing (as a component of existing screening tools for the early detection of cognitive impairment) is of value for the determination of cognitive impairment, as compared to the visual-spatial component of a more comprehensive computerized neurocognitive battery used for cognitive assessment.

Methods
=======

We performed a retrospective analysis based on medical records from the years 2005 to 2010 of patients seen at the comprehensive geriatric assessment (CGA) unit of the Clalit Health Services in Beer Sheva, Israel. The multidisciplinary staff of the CGA unit include specialist geriatricians, geriatric nurses, a dietician, an occupational therapist, a physical therapist, and a social worker.

The study population included patients older than 65 years referred by the primary care physician for geriatric assessment. The assessment battery included the following components: 1) Demographics, including age, gender, and education level. 2) History and examination, with emphasis on medical history and physical examination, drug therapy, laboratory and other investigations (available via the computerized medical record system), psychosocial assessment, and nutritional status. 3) Depression screening by Patient Health Questionnaire.[@b18-cia-10-1881] 4) Basic Activity of Daily Living.[@b19-cia-10-1881],[@b20-cia-10-1881] 5) Instrumental Activity of Daily Living (the Older Americans Resources and Service Instrumental Activity of Daily Living).[@b21-cia-10-1881] 6) Comorbidity status (Charlson comorbidity index[@b22-cia-10-1881] and cumulative illness rating scale -- geriatric version).[@b23-cia-10-1881] 7) Cognitive screening was performed using the following instruments: a) Mini Mental State Examination, rated on a scale of 0--30;[@b24-cia-10-1881] b) Clock Drawing Test (CDT) rated on a scale of 0--2;[@b25-cia-10-1881],[@b26-cia-10-1881] c) Montreal Cognitive Assessment (MoCA) test rated on a scale of 0--30;[@b27-cia-10-1881] d) Neurotrax (Mindstreams) computerized cognitive assessment battery, validated for use in the elderly.[@b28-cia-10-1881]--[@b30-cia-10-1881]

The visual-spatial components of each of the aforementioned instruments were compared. A dichotomy score of either normal or abnormal was allocated for each of the tests as follows:

1\) Mini Mental State Examination: The intersecting pentagons were rated as normal (score 1) or abnormal (score 0). 2) CDT as normal (score 2) or abnormal (1 or 0). Scores were allocated as follows: 0 -- neither numbers nor hands are present, or they have been placed incorrectly; 1 -- the hands are present and they have been placed correctly, and numbers are either missing or incorrectly placed; 2 -- both hands and numbers are present and have been placed correctly. 3) Cube Drawing Test component of the MoCA test as normal (score 1) or abnormal (score 0). 4) Trail Making B test component of MoCA test as normal, where all points (letters and numbers) are connected in the correct order (score 1), or at least one point is missed or not in the correct sequence (score 0). 5) Visual-spatial index of the Neurotrax (Mindstreams) computerized cognitive assessment battery (a score of ≤85, representing one standard deviation \[SD\] below normal was scored as 0, and \>85 as 1).

A diagnosis of dementia was made according to *DSM-IV* criteria[@b31-cia-10-1881] and of MCI according to consensus criteria for MCI.[@b7-cia-10-1881],[@b9-cia-10-1881],[@b10-cia-10-1881]

The study was approved by the Ethics Committee of Clalit Health Services at the Meir Medical Center.

Statistical analysis
--------------------

We calculated sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for each of the measures for determining cognitive impairment. Sensitivity = true positive/gold standard positiveSpecificity = true negative/gold standard negativePPV = true positive/test outcome positiveNPV = true negative/test outcome negative

Using the visual-spatial index of the Neurotrax (Mind-streams) assessment battery as the reference,[@b28-cia-10-1881]--[@b30-cia-10-1881] the other tests were compared both individually and in varied combinations, in order to determine sensitivity and specificity, PPV, and NPV. Chi-square analysis was performed with *P*\<0.05 considered to be statistically significant.

Results
=======

Study population
----------------

A total of 190 patients assessed at the CGA unit over the years 2005--2010 with data available for all the study instruments were eligible for inclusion in the study ([Table 1](#t1-cia-10-1881){ref-type="table"}).

The average age and SD was 81.09±5.42 years (range: 67--94), and 111 (58.4%) were females. The mean education level was 13.83 years (SD ±10.02). Based on clinical and cognitive assessment, 62 (32.6%) of the patients were determined to be cognitively normal, 90 (47.4%) were diagnosed as having MCI, and 38 (20%) were diagnosed as having dementia. Of those with dementia, 27 (71%) patients were diagnosed with Alzheimer's disease, nine (23.8%) with vascular dementia, one (2.6%) with diffuse Lewy body dementia, and one (2.6%) with other dementia.

Cognitive evaluations
---------------------

The results of the cognitive assessments are presented in [Table 2](#t2-cia-10-1881){ref-type="table"}.

With regard to the Neurotrax computerized cognitive assessment, a total of 107 (56.3%) subjects scored below one SD from the normal (\<85%) on the global score index. For the visual-spatial index, 98 subjects (51.6%) scored below one SD.

With regard to abnormal results for the other cognitive tests, the Cube Test was abnormal in 64 subjects (33.7%), the Trail Making B test in 110 (57.9%), the Intersecting Pentagon Copying (IPC) test in 117 (61.6%) subjects, and the CDT was abnormal in 92 (48.4%).

Comparing the individual cognitive tests with that of the visual-spatial index of Neurotrax, we found the Trail Making B test to be most sensitive (72.4%) and the Cube Test to have the highest specificity (72.8%) ([Table 3](#t3-cia-10-1881){ref-type="table"}).

The effect of combining two different tests, Trail Making B and IPC, was a higher sensitivity of 87.8%. The highest specificity of combined tests was for Trail Making B test and the Cube Test (54.3%) ([Table 4](#t4-cia-10-1881){ref-type="table"}).

When looking at the combined effect of three tests compared to the visual-spatial index, the highest sensitivity was 88.8% for a combination of Trail Making B test, Cube Test, and IPC. This combination also had the highest specificity of 33.7% compared to other multiple combinations of tests. When looking at the combination of all four tests, the sensitivity was 93.9%, and specificity was 27.2% ([Table 5](#t5-cia-10-1881){ref-type="table"}).

Discussion
==========

Our results show that tests of visual-spatial function are useful for screening patients for impaired cognitive function. While most screening instruments currently in use include an evaluation of visual-spatial function as one component of the test,[@b24-cia-10-1881]--[@b29-cia-10-1881] no screening tool is based solely on this aspect of cognitive function. The high sensitivity found for the combination of all four tests that were administered was associated with a low specificity. Our results suggest that when at least one of the tests is abnormal, further cognitive assessment is indicated.

The high sensitivity of the combined tests may eliminate the need for further cognitive screening. The time required to administer these four tests varies from 3 to 5 minutes, which is certainly acceptable for screening. These tests are all simple paper-based tests that can be easily administered in the clinic or home setting by nonprofessional staff who have received the necessary training ([Table 5](#t5-cia-10-1881){ref-type="table"}).

To the best of our knowledge, this is the first such study to evaluate the combined value of screening tests for visual-spatial function in cognitive assessment. The use in this study of the Neurotrax visual-spatial index based on the Block Design of the Wechsler Adult Intelligence Scale-3[@b32-cia-10-1881] as the reference test, as well as the use of a cognitive diagnosis based on a CGA by a multidisciplinary team, strengthens the value of our findings.

Our study has a number of limitations. We performed a retrospective analysis based on the charts of patients referred to a single CGA unit in the southern district of Israel. Our patients spoke either Hebrew or Russian as their primary language and were all of Jewish ethnicity. Thus, the generalizability of our results is limited. The choice of a computerized cognitive assessment battery as the gold standard rather than formal neuropsychological assessment is a possible limitation. However, the Neurotrax battery has been well validated in numerous studies.[@b28-cia-10-1881]--[@b30-cia-10-1881] We realize that many of the tests that we used are not limited to visual-spatial function but that they assess other aspects of cognitive function as well, particularly executive function. The overlap with other cognitive functions may clearly have a confounding effect on our results.

We also acknowledge that most conditions causing the dementia syndrome present primarily with memory, language, and executive function deficits, at least initially, and that impaired visual-spatial function in itself does not constitute one of the usual diagnostic criteria ([Table 6](#t6-cia-10-1881){ref-type="table"}).

Conclusion
==========

The combination of four short, paper-based tests, namely the Trail Making B test, the Cube Test, the IPC test, and the CDT, was found to be highly sensitive (93.9%) for identifying subjects with cognitive impairment, when compared to the Neurotrax (Mindstreams) computerized cognitive assessment battery. The use of a combination of visual-spatial tests for screening in neurocognitive disorders should be evaluated in further prospective studies.
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###### 

Characteristics of study participations (N=190)

  Baseline variables                                                        N                       \%
  ------------------------------------------------------------------------- ----------------------- ------
  Sex                                                                                               
   Male                                                                     79                      41.6
   Female                                                                   111                     58.4
  Age (years)                                                                                       
   Range                                                                    67--94                  
   Mean ± SD                                                                81.09±5.42              
  Cognitive diagnosis                                                                               
   Normal                                                                   62                      32.6
   MCI                                                                      90                      47.4
   Dementia, total                                                          38                      20
   Alzheimer type                                                           27                      71
   Vascular type                                                            9                       23.8
   Lewy body type                                                           1                       2.6
   Others                                                                   1                       2.6
  Years of education                                                                                
   Range                                                                    0--25                   
   Mean ± SD                                                                13.83±10.02             
  Depression screening (by PHQ-9)                                                                   
   Total                                                                    127 (63 missing data)   
   Range                                                                    1--27                   
   Mean ± SD                                                                12.9±6.6                
  Basic Activity of Daily Living (BADL)                                                             
   Total                                                                    154 (36 missing data)   
   Range                                                                    35--100                 
   Mean ± SD                                                                92.06±11.89             
  Instrumental Activity of Daily Living (IADL)                                                      
   Total                                                                    146 (44 missing data)   
   Range                                                                    0--14                   
   Mean ± SD                                                                9.60±3.55               
  Charlson combined score (with age)                                                                
   Range                                                                    3--11                   
   Mean ± SD                                                                5.28±1.65               
  Total CIRS-G score                                                                                
   Range                                                                    4--19                   
   Mean ± SD                                                                10.91±4.66              
  Severity index (total CIRS-G score/total number of categories endorsed)                           
   Range                                                                    1.3--2.6                
   Mean ± SD                                                                1.99±0.27               

**Abbreviations:** SD, standard deviation; MCI, mild cognitive impairment; PH Q-9, Patient Health Questionnaire-9; CIRS-G, cumulative illness rating scale -- geriatric version.

###### 

Selected outcomes cognitive assessment of study population

  Cognitive assessment   N             \%
  ---------------------- ------------- ------
  Neurotrax                            
  Global score                         
   Normal                83            43.7
   Abnormal              107           56.3
   Mean ± SD             84.75±12.34   
   Range                 55.9--112.1   
  Visual-spatial index                 
   Normal                92            48.4
   Abnormal              98            51.6
   Mean ± SD             87.43±13.07   
   Range                 62.5--128.4   
  Cube Test                            
   Normal                126           66.3
   Abnormal              64            33.7
  Trail Making B test                  
   Normal                80            42.1
   Abnormal              110           57.9
  Pentagon Copying                     
   Normal                73            38.4
   Abnormal              117           61.6
  Clock Drawing Test                   
   Normal                98            51.6
   Abnormal              92            48.4

**Abbreviation:** SD, standard deviation.

###### 

Comparison between single tools and visual score of Neurotrax test for evaluation of visual-spatial ability

  Type of tests         Neurotrax visual-spatial index   Sensitivity(%)   Specificity (%)   PPV (%)   NPV (%)                         
  --------------------- -------------------------------- ---------------- ----------------- --------- ---------- ------ ------ ------ ------
  Cube Test                                                                                                                           
   Abnormal             39                               39.8             25                27.2      0.091      39.8   72.8   60.9   53.2
   Normal               59                               60.2             67                72.8                                      
  Trail Making B test                                                                                                                 
   Abnormal             71                               72.4             39                42.4      \<0.0001   72.4   57.6   64.5   66.3
   Normal               27                               27.6             53                57.6                                      
  Pentagon Copying                                                                                                                    
   Abnormal             67                               68.4             50                54.3      0.053      68.4   45.7   57.3   57.5
   Normal               31                               31.6             42                45.7                                      
  Clock Drawing Test                                                                                                                  
   Abnormal             64                               65.3             34                37.0      \<0.0001   65.3   63.0   65.3   63.0
   Normal               34                               34.7             58                63.0                                      

**Abbreviations:** PPV, positive predictive value; NPV, negative predictive value.

###### 

Comparison between two integrated single tools and visual score of Neurotrax test for evaluation of visual-spatial ability

  Combinations of tests        Neurotrax visual-spatial index   Sensitivity(%)   Specificity (%)   PPV (%)   NPV (%)                         
  ---------------------------- -------------------------------- ---------------- ----------------- --------- ---------- ------ ------ ------ ------
  Trail B + Cube Test                                                                                                                        
   Abnormal                    73                               74.5             42                45.7      \<0.0001   74.5   54.3   63.5   66.7
   Normal                      25                               25.5             50                54.3                                      
  CDT + Cube Test                                                                                                                            
   Abnormal                    72                               73.5             43                46.7      \<0.0001   73.5   53.3   62.6   65.3
   Normal                      26                               26.5             49                53.3                                      
  CDT + Trail B                                                                                                                              
   Abnormal                    83                               84.7             51                55.4      \<0.0001   84.7   44.6   61.9   73.2
   Normal                      15                               15.3             41                44.6                                      
  Trail B + Pentagon Copying                                                                                                                 
   Abnormal                    86                               87.8             61                66.3      \<0.0001   87.8   33.7   58.5   72.1
   Normal                      12                               12.2             31                33.7                                      
  CDT + Pentagon Copying                                                                                                                     
   Abnormal                    81                               82.7             59                64.1      \<0.001    82.7   35.9   57.9   66.0
   Normal                      17                               17.3             33                35.9                                      
  Cube + Pentagon Copying                                                                                                                    
   Abnormal                    74                               75.5             52                56.5      \<0.001    75.5   43.5   58.7   62.5
   Normal                      24                               24.5             40                43.5                                      

**Abbreviations:** PPV, positive predictive value; NPV, negative predictive value; CDT, Clock Drawing Test.

###### 

Comparison between three and four integrated tools and visual score of Neurotrax test for evaluation of visual-spatial ability

  Type of tests               Neurotrax visual-spatial index   Sensitivity (%)   Specificity (%)   PPV (%)   NPV (%)                         
  --------------------------- -------------------------------- ----------------- ----------------- --------- ---------- ------ ------ ------ ------
  Cube + Pentagon + Trail B                                                                                                                  
   Abnormal                   87                               88.8              61                66.3      \<0.0001   88.8   33.7   58.8   73.8
   Normal                     11                               11.2              31                33.7                                      
  CDT + Cube + Pentagon       \+ Trail B                                                                                                     
   Abnormal                   92                               93.9              67                72.8      \<0.0001   93.9   27.2   57.9   80.6
   Normal                     6                                6.1               25                27.2                                      

**Abbreviations:** PPV, positive predictive value; NPV, negative predictive value; CDT, Clock Drawing Test.

###### 

Sensitivity and specificity of individual tests compared with clinical diagnosis

  Type of tests                Diagnosis   Sensitivity (%)   Specificity (%)   PPV (%)   NPV (%)                        
  ---------------------------- ----------- ----------------- ----------------- --------- --------- ------ ------ ------ ------
  Cube Test                                                                                                             
   Abnormal                    49          38.3              15                24.2      0.07      38.3   75.8   76.6   37.3
   Normal                      79          61.7              47                75.8                                     
                               128                           62                                                         
  Trail B test                                                                                                          
   Abnormal                    80          62.5              30                48.4      0.08      62.5   51.6   72.7   40.0
   Normal                      48          37.5              32                51.6                                     
                               128                           62                                                         
  Pentagon                                                                                                              
   Abnormal                    79          61.7              38                61.3      1.0       61.7   38.7   67.5   32.9
   Normal                      49          38.3              24                38.7                                     
                               128                           62                                                         
  CDT total                                                                                                             
   Abnormal                    74          57.8              24                38.7      0.02      57.8   61.3   75.5   41.3
   Normal                      54          42.2              38                61.3                                     
                               128                           62                                                         
  Neurotrax exam total score                                                                                            
   Abnormal                    84          65.6              23                37.1      \<0.01    65.6   62.9   78.5   47.0
   Normal                      44          34.4              39                62.9                                     
                               128                           62                                                         

**Abbreviations:** PPV, positive predictive value; NPV, negative predictive value; MCI, mild cognitive impairment; CDT, Clock Drawing Test.
